National Brain Tumor Society Starts $2.5M Capital Campaign
September 20, 2016 The National Brain Tumor Society, a national nonprofit based in Newton that is seeking better treatments and a cure for brain tumors, yesterday announced the launch of its first capital campaign, which aims to raise $2.5 million to improve clinical outcomes for children suffering from brain tumors.
The National Brain Tumor Society
(NBTS) said the campaign, called Project Impact
, seeks to initially raise at least $2.5 million in specialty gifts and funds over five years to resource the launch of scientific projects within the Defeat Pediatric Brain Tumors Research Collaborative, an international research effort.
The Collaborative, which has been in development with since 2014, has been structured to accelerate research from discovery to clinical trials. NBTS has created a subsidiary, Pediatric Cancer Cure, LLC, to govern the Collaborative.
Researching and developing new treatments for pediatric brain tumors is a particularly challenging task, which faces multiple but interrelated barriers that span the research and development spectrum from small patient populations, lack of effective preclinical models, to complex basic biology, regulatory hurdles and economic disincentives, said David Arons, NBTS chief executive officer.
To overcome these complex challenges, and get better treatments to patients, we needed to create an equally sophisticated intervention," he noted. "We believe that having groups with complementary skills work together in a coordinated effort, sharing data and expertise, and tackling the problem from multiple angles as one team is the starting point for greater and faster progress.
NBTS will be responsible for administrative activities of the Collaborative, such as negotiating agreements, managing the budget and finances, managing the intellectual property portfolio, conducting marketing and communications, providing data and infrastructure support, coordinating meetings and research reviews, and driving fundraising efforts.
Leading the capital campaign are Michael Nathanson, NBTS board chairman, and Cord Schloboh, a practicing dentist whose daughter died from pediatric high-grade glioma.
A new report, issued last week by the federal Centers for Disease Control, on Friday confirmed, that pediatric brain tumors have now replaced leukemias as the deadliest cancers in children and adolescents, accounting for 3 out of every 10 cancer deaths in that population.
To date, no drug has developed specifically to treat pediatric brain tumors, and few standards of care or treatment options exist for children with brain tumors, according to NBTS. In particular, pediatric high-grade gliomas have no standard of care. Overall, less than 30% of all children with high-grade gliomas survive more than five years.
NBTS supports more than 23 regional walks, races and rides, and other community and scientific events.